Arsenic trioxide induces apoptosis and the formation of reactive oxygen species in rat glioma cells
Arsenic trioxide (As2O3) has a dramatic therapeutic effect on acute promyelocytic leukemia (APL) patients. It can also cause apoptosis in various tumor cells. This study investigated whether As2O3 has an antitumor effect on glioma and explored the underlying mechanism.
MTT and trypan blue assays showed that As2O3 remarkably inhibited growth of C6 and 9 L glioma cells. Cell viability decreased in glioma cells to a greater extent than in normal glia cells. The annexin V-FITC/PI and Hoechest/PI staining assays revealed a significant increase in apoptosis that correlated with the duration of As2O3 treatment and occurred in glioma cells to a greater extent than in normal glial cells. As2O3 treatment induced reactive oxygen species (ROS) production in C6 and 9 L cells in a time-dependent manner. Cells pretreated with the antioxidant N-acetylcysteine (NAC) showed significantly lower As2O3-induced ROS generation. As2O3 significantly inhibited the expression of the anti-apoptotic gene Bcl-2, and upregulated the proapoptotic gene Bax in both C6 and 9 L glioma cells in a time-dependent manner.
As2O3 can significantly inhibit the growth of glioma cells and it can induce cell apoptosis in a time- and concentration-dependent manner. ROS were found to be responsible for apoptosis in glioma cells induced by As2O3. These results suggest As2O3 is a promising agent for the treatment of glioma.
KeywordsArsenic trioxide (As2O3) Reactive oxygen species (ROS) Glioma Apoptosis
Dulbecco’s modified Eagle’s medium
Fetal calf serum
Phosphate buffered saline
Reaction oxygen species
Despite commonly being known as a toxic metalloid, arsenic trioxide (As2O3) has applications in traditional medicine in China. As early as the 1970s, a research group at the First Affiliated Hospital of Harbin Medical University discovered that As2O3 can induce remissions in up to 70% of acute promyelocytic leukemia (APL) patients [1, 2]. The dramatic therapeutic effect of As2O3 on APL was achieved primarily through the induction of cell differentiation and apoptosis [2, 3]. At low concentrations, As2O3 promoted cell differentiation, while at concentrations above 0.5 μmol/l, it induced cell apoptosis [4, 5].
As2O3 induced apoptosis not only in NB4 cells (an APL cell line) but also in various other tumor cell lines [6, 7]. The underlying mechanism remained unclear, but inhibition of cell differentiation and growth and induction of apoptosis are speculated to be the general mechanisms for tumor treatment  and As2O3 action [9, 10]. Further research on As2O3 in APL showed that reactive oxygen species (ROS) play an important role in the induction of apoptosis, and that APL cells are sensitive to the intracellular ROS levels . However, there is still some discussion about whether ROS are involved in As2O3 inhibition of the growth of tumor cells [11, 12, 13, 14].
Due to the existence of the blood–brain barrier, it is hard for therapeutics drugs to affect glioma cells. New therapeutics are required to overcome this challenge. Although it is still unclear how As2O3 could cross the blood–brain barrier, several studies of As2O3 in glioma indicate that it is a potential therapeutic agent for this type of cancer [9, 15].
The effective concentrations of As2O3 applied in those studies were extremely high, ranging from 4.0 μM to 5.0 mM [16, 17]. High concentrations of As2O3 carry a major health risk. Side effects include mild gastrointestinal discomfort, transient elevation of liver enzymes, reversible neuropathy, hypokalemia, hyperglycemia and cardiac toxicity. Prolongation of the life quality has been detected in as many as 38% of patients treated with As2O3 [18, 19]. In this study, we investigated the anti-tumor effect of a low concentration range (0–8 μmol/l) of As2O3 in the glioma cell lines C6 and 9 L, assessed changes to non-tumor (glial) cells, and explored the underlying mechanism by studying ROS.
As2O3 was obtained from Yida. Stock solutions were prepared in phosphate buffered saline (PBS) to exclude any unknown influence from other solvents. Working solutions were diluted in RPMI-1640 medium (Gibco) and Dulbecco’s modified Eagle’s medium (DMEM; Gibco), supplemented with 10% heat-inactivated fetal calf serum (FCS).
Rat C6 and 9 L glioma cells were obtained from Harbin Medical Neurosurgical Institute and were respectively cultured in 10% RPMI-1640 medium and 10% DMEM, in both cases supplemented with 10% FCS. Primary glial cells were isolated from new suckling Wistar mice within 24 h of birth using the method of McCarthy and de Vellis . The cell concentration was adjusted to 5 × 105 cells/ml in 15% DMEM. The fourth generation (after about 20 days of culture) was used. The cells were maintained at 37 °C, 95% air and 5% CO2 in a humidified incubator (Heraeus).
Determination of cell viability
To test cell viability, cell suspensions of 2 × 105 cells/ml were mixed with 0.4% trypan blue. After 5–10 min, dye exclusion was examined for viable cells under a light microscope. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) bromide assay was also used to determine the number of viable cells after exposure to As2O3. 200 μl cell suspensions (4 × 104 cells/ml) were seeded in 96-well plates. Serially diluted As2O3 was added at final concentrations of 0 (control), 0.5, 1.0, 3.0, 5.0, 6.0, 7.0 and 8.0 μmol/l. Each experiment was performed in quadruplicate and repeated at least three times. After 24, 48 and 72 h, the MTT products were quantified and the results were presented as the percentage of viable cells and normalized to the level of controls. The optimal concentration was determined as 5.0 μmol/l and used to treat the rat C6 and 9 L cells.
Measurement of apoptosis
After cultured for 24, 48 and 72 h, cell apoptosis was assessed using propidium iodide (PI) and annexin-V conjugated to fluorescein isothiocyanate (FITC) according to the manufacturer’s instructions (BD Biosciences). Briefly, cells with or without As2O3 were incubated with FITC-conjugated annexin-V. Then, the cells were collected, washed and centrifuged at 200 g for 10 min. The cell pellet was gently resuspended in 200 μl PI and incubated in the dark for 30 min at room temperature. Apoptosis was then assessed using flow cytometry.
Cell apoptosis and necrosis were further examined by staining with Hoechst 33,342 (HOE) and PI, respectively. Cells were plated into 96-well plates and treated with 5.0 μmol/l As2O3 for 24, 48 and 72 h. Cells (5 × 106 cells/ml) were incubated for 15 min at 37 °C with HOE (10 μg/ml in PBS), centrifuged, washed in PBS, and resuspended at density of 1 × 107 cells/ml. PI (50 μg/ml in PBS) was added before observation. Cells were examined using a light microscope (Olympus) equipped with a fluorescent light source and a UV-2A filter cube with an excitation wavelength of 330–380 nm and a barrier filter of 420 nm. All experiments were repeated at least three times.
Measurement of ROS levels
The generation of ROS was measured as previously described . Briefly, cell suspensions (2 × 106 cells/ml) were exposed to As2O3 at 5.0 μmol/l for 24, 48 and 72 h. To evaluate the major organelles that governed the ROS-mediated stress in glioma cells, C6 and 9 L cells were pretreated with 5 nM antioxidant N-acetylcysteine (NAC) for 2 h, and were exposed to As2O3 at 5.0 μmol/l for 24 h . After exposure, cells were incubated in 10 μM of 2′,7′-dichlorofluorescein diacetate (DCFH-DA; Molecular Probes) at 37 °C for 30 min. The cells were harvested and washed with cold PBS three times. Then, ROS levels were determined through fluorescence-activated cell sorting.
Measurement of apoptotic proteins
Levels of apoptosis-related proteins (Bcl-2, Bax and Fas) were analyzed using Western blot as previously described . Briefly, cells were lysed at 4 °C via RIPA. Proteins were separated using 10% SDS-PAGE, transferred to nitrocellulose membranes and incubated with primary antibodies against Bcl-2, Bax, Fas and actin (1:100, Santa Cruz Biotechnology). Then, the membranes were incubated with horseradish peroxidase-conjugated secondary antibodies, and detected using an enhanced chemiluminescence (ECL) kit (Beyotime).
All quantitative data measurements were performed in triplicate and the results are presented as means ± standard deviation. One-way analysis of variance (ANOVA) was performed. The post hoc tests were Dunnett’s tests. Probability values (p) less than 0.05 were considered statistically significant.
As2O3 decreased cell viability in C6 and 9 L glioma cells
The trypan blue assay showed that 5.0 μmol/l As2O3 significantly decreased cell viabilities in C6 and 9 L in a time-dependent manner (Fig. 1b). Although the cell viability in normal glial cells was also significantly decreased, the change was smaller than for glioma cells, suggesting a greater inhibitory role in glioma than in glial cells.
As2O3 induced apoptosis in C6 and 9 L glioma cells
Production of ROS in C6 and 9 L glioma cells exposed to As2O3
Effects of As2O3 on the expression of apoptotic proteins Bcl-2, Bax and Fas
Because of its ability to induce apoptosis in various malignant tumor cells, As2O3 has potential as a treatment agent for malignant tumors [24, 25]. Gliomas are highly aggressive tumors that respond poorly to existing clinical therapeutic agents. In previous studies, it was shown that As2O3 treatment could inhibit cell growth of glioma cells, but the studies did not yield guidance on the effective doses [26, 27, 28].
Here, we investigated the effective doses of As2O3 using rat glioma cells and comparing them with non-tumor glial cells. Our results showed that As2O3 inhibited the growth of glioma cells in time- and concentration-dependent manners, and that 5.0 μmol/l As2O3 is the optimum concentration for inhibiting cell viability in both C6 and 9 L glioma cells. The inhibitory rate for non-tumor cells was less than 10% of that for the glioma cells, indicating that As2O3 is a promising drug. Due to the exist of the blood–brain barrier, it remains unclear how the 5 μmol/l concentration can be obtained in human blood such that it would be useful for treating glioma cells. Further studies using in vivo animal models are needed.
Both the HOE/PI and annexin-V/PI assays showed that 5.0 μM As2O3 induced apoptosis. However, the mechanism of apoptosis in solid tumor cells is far from clear. In glioma cells treated with As2O3, one of the most likely mechanisms for triggering an antitumor effect is the induction of ROS [29, 30]. Like other heavy metals, including iron, copper, chromium, cadmium, lead and mercury, arsenic affects cells by causing oxidative damage, primarily through disruption of the endogenous cellular antioxidant–redox balance [29, 30]. Cysteine thiol is the functional site for most redox proteins. Arsenic can directly bind to this site and destroy protein function, thereby affecting ROS production and clearance [29, 30]. Cell viability, ROS levels, apoptosis and autophagy in human glioblastoma cell line have been shown to be regulated by As2O3 [31, 32] and/or As2O3 in combination with other agents . As2O3 induces ROS production and apoptosis in glioma cells through the upregulation of the mitoferrin-2 gene . Consistently with the results of those studies, we also found that intracellular ROS levels increased significantly after As2O3 treatment.
The brain appears to be especially sensitive to ROS stress when compared to other organs. Although comprising only 2% of human body weight, the human brain consumes up to 20% of the oxygen supply. Such a high level of oxygen consumption indicates that large quantities of ROS are generated during oxidative phosphorylation in brain tissue. In addition, iron content has been shown to increase brain sites in which ROS production may be greater . Tumor cells are vulnerable to ROS stress. Thus, therapeutic approaches directed at ROS intervention may have an antitumor effect, and As2O3 is a promising antitumor reagent for gliomas.
As2O3 downregulated the expression of Bcl-2, an anti-apoptotic protein, and upregulated the expression of Bax, a pro-apoptotic protein, thus shifting the Bax/Bcl-2 ratio in favor of apoptosis. Fas protein expression remained unchanged. These findings indicate that Bcl-2 and Bax play an important role in As2O3-induced apoptosis in C6 and 9 L glioma cells.
Our results hinted at the possible involvement of mitochondrial dysfunction in As2O3-induced apoptosis. The Bcl-2 family of proteins appear to control cell death by regulating mitochondrial physiology . A change in the mitochondrial electrochemical potential results in the release of apoptotic proteins, such as cytochrome c, Smac/DIABLO, pro-caspases 2, 3 and 9, and apoptosis-inducing factor.
Under physiological and pathophysiological conditions, ROS contributes to trigger and mediate apoptosis . The mitochondria are highly susceptible to oxidative damage, and Bcl-2 exerts its anti-apoptotic function by reducing intracellular ROS. As2O3 downregulated Bcl-2 and rendered C6 and 9 L glioma cells vulnerable to apoptotic cell death. In cells pretreated with NAC, As2O3-induced apoptosis was inhibited, suggesting that a mitochondrial death pathway plays an important role in As2O3-induced apoptosis.
As2O3 strongly inhibits cell viability and induces apoptosis of rat C6 and 9 L glioma cells in vitro when used at an optimal concentration of 5 μmol/l. This action is related to the induction of ROS generation. Moreover, As2O3 showed lower cytotoxicity to normal glial cells than glioma cells, indicating that As2O3 may be a potentially potent chemotherapeutic agent for treating brain tumors.
This study was supported by the National Natural Science Foundation of China (Grant No. 30600641) and the Administration of Education, Heilongjiang Province (Grant No. 11511209).
Availability of data and materials
Please contact the author with data requests.
YS, CW, LW and ZD performed the experiments. All the authors contributed to the data analysis and manuscript preparation. All authors read and approved the final manuscript.
Ethics approval and consent to participate
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- 2.Nellessen CM, Janzen V, Mayer K, Giovannini G, Gembruch U, Brossart P, Merz WM. Successful treatment of acute promyelocytic leukemia in pregnancy with single-agent all-trans retinoic acid. Arch Gynecol Obstet. 2017; https://doi.org/10.1007/s00404-017-4583-6.
- 3.Hassani S, Khaleghian A, Ahmadian S, Alizadeh S, Alimoghaddam K, Ghavamzadeh A, Ghaffari SH. Redistribution of cell cycle by arsenic trioxide is associated with demethylation and expression changes of cell cycle related genes in acute promyelocytic leukemia cell line (NB4). Ann Hematol. 2017; https://doi.org/10.1007/s00277-017-3163-y.
- 4.Chen GQ, Zhu J, Shi XG, Ni JH, Zhong HJ, Si GY, Jin XL, Tang W, Li XS, Xong SM, Shen ZX, Sun GL, Ma J, Zhang P, Zhang TD, Gazin C, Naoe T, Chen SJ, Wang ZY, Chen Z. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood. 1996;88:1052–61.PubMedGoogle Scholar
- 5.Chen GQ, Shi XG, Tang W, Xiong SM, Zhu J, Cai X, Han ZG, Ni JH, Shi GY, Jia PM, Liu MM, He KL, Niu C, Ma J, Zhang P, Zhang TD, Paul P, Naoe T, Kitamura K, Miller W, Waxman S, Wang ZY, De The H, Chen SJ, Chen Z. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood. 1997;89:3345–53.PubMedGoogle Scholar
- 6.Zhang P, Zhao X, Zhang W, He A, Lei B, Zhang W, Chen Y. Leukemia-associated gene MLAA-34 reduces arsenic trioxide-induced apoptosis in HeLa cells via activation of the Wnt/beta-catenin signaling pathway. PLoS One. 2017;12:e0186868. https://doi.org/10.1371/journal.pone.0186868.CrossRefPubMedPubMedCentralGoogle Scholar
- 8.Zeng Y, Liu X, Yan Z, Xie L. Sphingosine 1-phosphate regulates proliferation, cell cycle and apoptosis of hepatocellular carcinoma cells via syndecan-1. Prog Biophys Mol Biol. 2017; https://doi.org/10.1016/j.pbiomolbio.2017.11.006.
- 10.Pan L, Li Y, Zhang HY, Zheng Y, Liu XL, Hu Z, Wang Y, Wang J, Cai YH, Liu Q, Chen WL, Guo Y, Huang YM, Qian F, Jin L, Wang J, Wang SY. DHX15 is associated with poor prognosis in acute myeloid leukemia (AML) and regulates cell apoptosis via the NF-kB signaling pathway. Oncotarget. 2017;8:89643–54. https://doi.org/10.18632/oncotarget.20288.PubMedPubMedCentralGoogle Scholar
- 14.Kajiguchi T, Yamamoto K, Hossain K, Akhand AA, Nakashima I, Naoe T, Saito H, Emi Sustained N. Activation of c-jun-terminal kinase (JNK) is closely related to arsenic trioxide-induced apoptosis in an acute myeloid leukemia (M2)-derived cell line, NKM-1. Leukemia. 2003;17:2189–95. https://doi.org/10.1038/sj.leu.2403120.CrossRefPubMedGoogle Scholar
- 23.Zeng Y, Yao X, Chen L, Yan Z, Liu J, Zhang Y, Feng T, Wu J, Liu X. Sphingosine-1-phosphate induced epithelial-mesenchymal transition of hepatocellular carcinoma via an MMP-7/ syndecan-1/TGF-beta autocrine loop. Oncotarget. 2016;7:63324–37. https://doi.org/10.18632/oncotarget.11450.PubMedPubMedCentralGoogle Scholar
- 24.Klinger PH, Andrade AF, Delsin LE, Queiroz RG, Scrideli CA, Tone LG, Valera ET. Inhibition of SHH pathway mechanisms by arsenic trioxide in pediatric medulloblastomas: a comprehensive literature review. Genet Mol Res. 2017;16 https://doi.org/10.4238/gmr16019412.
- 25.Chang HR, Munkhjargal A, Kim MJ, Park SY, Jung E, Ryu JH, Yang Y, Lim JS, Kim Y. The functional roles of PML nuclear bodies in genome maintenance. Mutat Res. 2017; https://doi.org/10.1016/j.mrfmmm.2017.05.002.
- 31.Pucer A, Castino R, Mirkovic B, Falnoga I, Slejkovec Z, Isidoro C, Lah TT. Differential Role of cathepsins B and L in autophagy-associated cell death induced by arsenic trioxide in U87 human glioblastoma cells. Biol Chem. 2010;391:519–31. https://doi.org/10.1515/bc.2010.050.CrossRefPubMedGoogle Scholar
- 32.Primon M, Huszthy PC, Motaln H, Talasila KM, Torkar A, Bjerkvig R, Lah Turnsek T. Cathepsin L silencing enhances arsenic trioxide mediated in vitro cytotoxicity and apoptosis in glioblastoma U87MG spheroids. Exp Cell Res. 2013;319:2637–48. https://doi.org/10.1016/j.yexcr.2013.08.011.CrossRefPubMedGoogle Scholar
- 33.Klauser E, Gulden M, Maser E, Seibert S, Seibert H. Additivity, antagonism, and synergy in arsenic trioxide-induced growth inhibition of C6 glioma cells: effects of genistein, quercetin and buthionine-sulfoximine. Food Chem Toxicol. 2014;67:212–21. https://doi.org/10.1016/j.fct.2014.02.039.CrossRefPubMedGoogle Scholar
- 36.Kitazawa H, Numakawa T, Adachi N, Kumamaru E, Tuerxun T, Kudo M, Kunugi H. Cyclophosphamide promotes cell survival via activation of intracellular signaling in cultured cortical neurons. Neurosci Lett. 2010;470:139–44. https://doi.org/10.1016/j.neulet.2009.12.073. S0304-3940(09)01677-2CrossRefPubMedGoogle Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.